 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the Company ) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to...

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium

Fulcrum Therapeutics, Inc. (NASDAQ:FULC  Get Free Report)s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $10.10, but opened at...

Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down to $10.10

CAMBRIDGE, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the...

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Over the last three days, A.I.dvisor has detected that FULC's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Fulcrum Therapeutics (FULC, $11.36) Aroon Indicator entered an Uptrend on March 15, 2024.

Fulcrum Therapeutics (FULC, $11.2) Aroon Indicator entered an Uptrend on March 14, 2024.

Fulcrum Therapeutics (FULC, $11.36) Aroon Indicator entered an Uptrend on March 13, 2024.

Equities research analysts at Royal Bank of Canada began coverage on shares of Fulcrum Therapeutics (NASDAQ:FULC  Get Free Report) in a note issued to investors on Wednesday, Briefing.com...

Fulcrum Therapeutics (NASDAQ:FULC) Receives New Coverage from Analysts at Royal Bank of Canada

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

RBC Capital starts Fulcrum Therapeutics at Outperform, sees two pipeline shots

Fulcrum Therapeutics (FULC, $10.91) Aroon Indicator entered an Uptrend on March 12, 2024.

Fulcrum Therapeutics (FULC, $11.28) Aroon Indicator entered an Uptrend on March 11, 2024.

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Volume (M)	555,124.00
52-Wk High	$13.70
52-Wk Low	$2.43

FULC Fulcrum Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals